AstraZeneca Reportedly Eyes Bristol Myers Squibb in Potential Pharma Mega-Deal

AstraZeneca is examining a potential takeover of Bristol Myers Squibb in a move that would reshape the pharmaceutical landscape, the Financial Times reported. Both companies have declined to comment on the speculation.

Analyst View: Patent Cliffs Limit Appeal

Analysts at Barclays noted that they do not view a deal as imminent, highlighting significant headwinds for Bristol Myers Squibb (BMS). While BMS's core business generates strong cash flow that would create synergies for a buyer, these benefits are tempered by looming losses of market exclusivity for its blockbuster drugs.

Two of the company's most important products are scheduled to face U.S. generic or biosimilar competition in 2028:

• The oncology drug Opdivo, which consensus estimates project will generate over $10 billion in revenue this year and next.
• The blood thinner Eliquis, for which BMS recently raised its fiscal 2026 guidance.

Ad

Pipeline Holds Key to Valuation

Barclays' analysis underscores the critical importance of Bristol Myers' drug development pipeline to its long-term value. The bank's current net present value (NPV) for BMS is $77.70 per share, which incorporates specific probabilities of success for key experimental drugs, including milvexian for atrial fibrillation and Cobenfy for Alzheimer’s disease psychosis.

The valuation hinges heavily on clinical trial outcomes. Barclays estimates that if all pipeline programs succeed, the valuation could increase to $88.20 per share, representing a 35% premium over Friday's closing price. Conversely, if all programs fail, the valuation would fall to $63.10 per share, or 3% below Friday's close, illustrating the risk-reward profile any potential acquirer would face.